Comparison of three commercially available buffy coat pooling sets for the preparation of platelet concentrates by Feys, Hendrik et al.
Vox Sanguinis (2018) 113, 555–561
ORIGINAL PAPER © 2018 The Authors.Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion
DOI: 10.1111/vox.12668
Comparison of three commercially available buffy coat
pooling sets for the preparation of platelet concentrates
H. B. Feys,1,2 R. Devloo,1 B. Sabot,3 J. Coene3 & V. Compernolle1,2,3
1Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium
2Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
3Blood Service of the Belgian Red Cross-Flanders, Ghent, Belgium
Received: 7 February 2018,
revised 16 April 2018,
accepted 2 May 2018,
published online 24 May 2018
Background A disposable set for platelet concentrate (PC) preparation by the
buffy coat method allows pooling of buffy coats, centrifugation and cell separa-
tion with in-line leucocyte filtration. This study compares three commercially
available pooling sets in combination with INTERCEPT pathogen inactivation
(PI).
Materials and methods Sets for pooling of buffy coats were from Fresenius Kabi
(FRE), Macopharma (MAC) and Terumo BCT (TER). Platelet yield, recovery and
concentration were compared before and after PI (n = 20). Platelet quality was
assessed by annexin V binding, P-selectin expression and PAC1 binding.
Results The TER pooling set had the highest platelet yield (539 – 044 9 1011)
compared with MAC (453 – 077) and FRE (456 – 051) prior to PI. This was
the result of a significantly higher platelet concentration in the TER storage bag
(141 – 012 9 106/lL) compared with MAC (118 – 019) and FRE (128 – 015).
However, the TER platelet content decreased by 156% after PI, yielding
455 – 047 9 1011 platelets compared with smaller reductions at 95% for MAC
(410 – 069) and 44% for FRE (436 – 052). None of the individual PC con-
tained >106 leucocytes. The pH in TER PC was lower compared with MAC and
FRE caused by a higher lactic acid production rate. Consequently, PAC1 binding
after TRAP activation was lowest for TER PC on day 6. P-selectin and annexin V
were not different between suppliers.
Conclusion This study demonstrates the added value of evaluating the entire
component production process when introducing a new consumable. This study
helped to inform a decision on what pooling set is ideally suited for routine
implementation taking into account PI.
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Introduction
The Belgian Red Cross-Flanders Blood Service issues
approximately 39,000 platelet concentrates (PC) per year
to hospitals in the Northern part of Belgium (Flanders).
About 40% of these are prepared by apheresis, the major
number is prepared by manual pooling of buffy coats
derived from whole blood donations.
Following donation, whole blood is stored overnight in
sealed temperature-controlled cases [1] awaiting compo-
nent preparation the next morning. Manual pooling is by
six buffy coats per concentrate. This high number is cho-
sen because a minimal platelet content of 30 9 1011 pla-
telets has been set by the Belgian competent authority
[2]. During pooling of buffy coats, platelet additive solu-
tion is added and after centrifugation and transfer to the
final storage bag of the set, all PCs are transferred to a
new disposable set for treatment with amotosalen and
UV-A light pathogen inactivation (PI) (INTERCEPT Blood
System, Cerus Corp, CA) [3, 4]. Until August 2017,
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pooling sets were purchased from Fenwal (part of Frese-
nius SE & Co, Bad Homburg, Germany) but their produc-
tion line ceased its activities and a new supplier had to
be chosen.
Three competing manufacturers of pooling sets were
entered in an independent comparative study. Platelet
yield and platelet quality were determined at different
time-points during and after PC preparation. The primary
criteria for PC prepared by each of these pooling sets
were (1) effective leucocyte depletion (<106 leucocytes per
unit), (2) compatibility with the available equipment
including separators, centrifuges and PI sets and (3) fulfil




Pooling sets from three different manufacturers were
selected for comparative analysis based on a product
requirements list. The three pooling sets were PT52600/6
from Fresenius Kabi (FRE), TRV8006XU from Macopharma
(MAC) (Tourcoing, France) and TF*RP0610M1 from Teru-
moBCT (TER) (Lakewood, CO). Twenty platelet concen-
trates were prepared (n = 20) with each pooling set. The
platelet yield was determined relative to the number of
platelets present in the primary buffy coats used for each
individual product. Figure 1 shows a model of the study
design and PC preparation process. Platelets were counted
using an automated blood cell counter of the types XN-10
or XS1000i (Sysmex, Kobe, Japan). Platelet quality was
determined immediately after PI on day 1 and following
5 days of storage in a standard platelet incubator with
agitation. To assess the pooling sets in routine use, a lar-
ger cohort of platelet concentrates (n = 50) was produced.
In this series only platelet content after PI was determined,
in the final platelet concentrate bag.
Platelet concentrate preparation
All pooling sets were of the octopus type consisting of (i)
multiple tubing ends for connecting buffy coats and addi-
tive solution to (ii) an intermediary pooling bag, (iii) a
leucocyte reduction filter and a (iv) storage bag (Fig. 1).
The buffy coats were from voluntary whole blood dona-
tions. Six buffy coats were manually pooled as described
[4, 5]. A 280 ml fixed volume of PAS-E additive solution
(SSP+, Macopharma) was added. Acceptance levels for
plasma carryover were minimum 32% and maximum
47%. Next, the bag was centrifuged at 542 g for 450 s at
22°C to separate red and white cells from platelets. The
buoyant platelet suspension was then separated on an
automated separator (Macopress Smart, Macopharma) and
transferred to the storage bag whilst passing over a leuco-
cyte reduction filter and a detection system for haemo-
globin to prevent transfer of red cells. Next, the PCs were
treated with INTERCEPT PI as described [6]. After the
final adsorption step to remove residual amotosalen and
its photoproducts, PC was transferred to the storage bag
included in the PI disposable set and then stored in a
temperature-controlled cabinet with continuous agitation.
Samples were taken from (i) the intermediary buffy coat
pool before centrifugation, from (ii) the platelet concen-
trate before PI, (iii) after PI and (iv) after storage (Fig. 1).
Laboratory methods
Platelet concentrate volume was determined by weighing
at specified moments during processing. Volumetric mass
density used was 1028 g/ml. Plasma carryover was deter-
mined in the intermediary pool (Fig. 1) by weighing and
haematocrit (Hct %) determination. The equation used
was ðVtotðVtotHct%Þ280Þ
VtotðVtotHct%Þ , with Vtot the total volume deter-
mined by weighing and 280 ml the additive solution vol-
ume. Platelets were counted in a fourfold dilution in
Fig. 1 Study design. Each pooling set (dotted line) was designed to pool
six buffy coats into one intermediary pooling bag with additive solution
(SSP+). Soft spin centrifugation and automated separation over a leu-
coreduction ﬁlter yielded a standard PC (before PI). These were then
treated with PI and stored on the agitator from day 1 on (ﬁnal PC D1).
All concentrates were stored for 5 days. A ﬁnal sample was taken on day
6 (ﬁnal PC D6). Samples were taken where indicated (sampling). Platelet
yield and quality were determined in these samples.
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saline using an automated haematology analyser (Sysmex
XS-1000i, Sysmex Corp, Japan). Recoveries were calcu-
lated relative to the sum of all platelets measured in each
of the six composing buffy coats (set as a 100%). Quality
control included determination of pH, glucose and lactic
acid levels using a point-of-care blood gas analyser
(RAPIDPoint, Siemens Healthineers, Erlangen, Germany).
Leucocytes were counted by flow cytometry on a FACS
Canto II using the LeukoCOUNT Combo Control kit (both
(BD Biosciences, Erembodegem, Belgium) according to the
manufacturer’s instructions.
Flow cytometry was performed essentially as described
[4]. In brief, expression of P-selectin (anti-CD62P~phy-
coerythrin, BD Biosciences), activated integrin aIIbb3
(PAC1~fluorescein, BD Biosciences) and phosphatidylser-
ine (annexin V~peridinin chlorophyll-Cy55; BD Bio-
sciences) was determined using an acoustic focusing flow
cytometer (Attune, Life Technologies, Carlsbad, CA, USA).
Isotype negative control antibodies were fluorescein
labelled IgM, clone G155-228 and phycoerythrin labelled
IgG, clone X40 (BD Biosciences). Platelets were incubated
with labelled antibodies or ligand for 10 min at room
temperature in 10 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES) buffer, pH 74 with 09%
(w/v) NaCl (HBS), 1 mM MgSO4 and 5 mM KCl, then
diluted a thousand fold immediately before readout as
described before [7]. For annexin V measurements, buf-
fers were supplemented with 2 mM CaCl2. As a negative
control, a buffer without CaCl2 was used. For
measurements of integrin aIIbb3 activation on stimulated
platelets, the PAR1 agonist thrombin-related activating
hexapeptide SFLLRN (TRAP, Sigma-Aldrich, St Louis, MO,
USA) was added at three different concentrations 4, 8 and
40 lM. The signals of the isotype antibody controls were
used to set threshold gates including 05% of 10,000 neg-
ative events. Percentage positive events were determined
of 10,000 cells stained for the platelet marker CD61 (anti-
CD61~allophycocyanin, Life Technologies).
Statistics
Sample means were compared by t-test or Mann–Whitney
test for parametric and nonparametric datasets, respec-
tively. For analysis with multiple variables, two-way
ANOVA with multiple comparisons was performed.
Results were considered significant if P values were smal-
ler than 005. Computational analysis was with Prism
(GraphPad Software Inc, La Jolla, CA, USA).
Results
The platelet content and recovery in the intermediary bag
after buffy coat pooling were not different between the
three suppliers (Fig. 2a,b and Table 1). In the storage bag
prior to PI, the TER set harvested significantly more pla-
telets than those from the other two suppliers (Fig. 2a,b
and Table 1). This could be explained by a better platelet
recovery per transferred volume in the TER pooling set,
Fig. 2 Platelet content and recovery. (a)
Platelet content at three different moments
during production: (○) intermediary pool, (□)
before pathogen inactivation, (M) after
pathogen inactivation. (b) Platelet recovery
relative to the amount of platelets in the
composing buffy coats, intermediary pool (open
bars), before (blue bars) and after (red bars)
pathogen inactivation. Bars are median, and
whiskers are range. (c) Platelet concentration at
three different moments during production:
(○) intermediary pool, (□) before pathogen
inactivation, (M) after pathogen inactivation.
(d) Plasma carryover for all three sets. Median
is the horizontal line, n ≥ 20. The horizontal
dotted lines indicate the acceptance levels.
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resulting in a higher platelet concentration compared with
MAC and FRE (Fig. 2c and Table 1). However, after PI,
this difference largely disappeared because 156% of pla-
telets were lost from the TER bag compared with 95%
and 44% for MAC and FRE, respectively. Still, the TER
pooling set could yield significantly more platelets than
the MAC bag set (Fig. 2a–c and Table 1). Plasma carry-
over was not different between sets (Fig. 2d), and none of
the individual products contained >106 leucocytes
(Fig. 3). A follow-up study to assess routine production of
PC (n = 50) confirmed that the TER pooling set resulted
in higher yields compared with those from MAC and FRE
after PI (Fig. 4).
The pH was lower on day 1 for PC prepared by the TER
pooling set compared with MAC and FRE (Fig. 5a, cir-
cles). As expected, product pH declined in function of
storage but none of the PC had levels below 64 on day 6
(Fig. 5a, diamonds). The lowest average pH on day 6 was
found in TER PC, reaching significance only in compar-
ison with MAC sets. For all three suppliers, a number of
PC had depleted glucose levels (Fig. 5b). Glucose levels
Table 1 Raw data to Figure 2a–c
FRE MAC TER Statistic
Platelet content (91011) Intermediary 647 (064) 642 (054) 661 (052)
Before PI 456 (051) 453 (077) 539 (044) (F vs. T)**
(M vs. T)****
After PI 436 (052) 410 (069) 455 (047) (M vs. T)*
Recovery (%) Intermediary 910 (35) 882 (30) 905 (41)
Before PI 683 (34) 619 (77) 738 (35) (F vs. T)****
(M vs. T)****
(F vs. M)****
After PI 675 (45) 560 (67) 622 (36) (F vs. T)****
(M vs. T)****
(F vs. M)****
Concentration (9106/lL) Intermediary 117 (012) 118 (010) 120 (010)
Before PI 128 (015) 118 (019) 141 (012) (F vs. T)**
(M vs. T)****
(F vs. M)*
After PI 120 (016) 112 (018) 125 (012) (M vs. T)***
Data are given as mean with SD between brackets (n = 20). Two-way ANOVA results are given by *P < 005; **P < 001; ***P < 0001 and ****P < 00001.
Fig. 3 Efﬁciency of leucodepletion. Leucocytes were counted by ﬂow
cytometry in a sample taken before PI, but after the pooling set routine.
Median and interquartile range are shown as horizontal lines and whis-
kers, respectively. Individual data are shown as open circles. The solid
horizontal line indicates that leucocytes were not observed in the
selected sample volume. The dotted horizontal line indicates the maximal
acceptable leucocyte count (Council of Europe Guidelines).
Fig. 4 Platelet content in a follow-up larger series. To assess routine use,
a larger series (n = 50) of platelet concentrates was produced using the
three different sets. Platelet content in the ﬁnal platelet concentrate bag
after PI was determined. All data are shown, bars represent median, and
whiskers represent range. ANOVA with multiple comparisons was per-
formed, statistic is indicated on top of each panel; *P < 005;
****P < 00001.
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were the lowest for PC prepared by the TER pooling set.
This corresponded with lactic acid production rates which
were highest for TER platelets (Fig. 5c,d).
Platelet function was assessed by integrin aIIbb3 activa-
tion in response to increasing concentrations of TRAP.
Integrin activation was lowest for the MAC platelets on
day 1 (Fig. 6a) compared with TER and FRE. After 5 day
storage, all platelets responded poorly to low and inter-
mediate TRAP concentrations. At high concentrations of
agonist, TER platelets responded the least compared with
MAC and FRE sets (Fig. 6b). Annexin V binding was the
highest for MAC platelets on day 1, reaching significance
in comparison with TER, not FRE (Fig. 7a). After storage,
annexin V binding was similar for all sets. Little differ-
ence could be noted in P-selectin expression (Fig. 7b)
which was lowest on day 1 for TER platelets, reaching
significance in comparison with FRE.
Discussion
There are several ways to prepare PC from blood dona-
tions [5]. Many blood institutions in the EU use the buffy
coat method among others to provide PC to patients. The
buffy coat method is considered gentle because it mini-
mally activates platelets [8]. The number of buffy coats
composing one PC depends on the blood institution and
national guidelines or legislation. In Belgium, a minimal
platelet content per adult transfusion is required since in
2011 the competent authority issued a circular that for
PI-treated PC the platelet content should be at least
3 9 1011. Therefore, six blood group matched buffy coats
are mixed and combined with additive solution to prepare
one PC.
The current study shows that MAC and FRE pooling
sets yield similar platelet quantities. In comparison, the
TER set yields significantly more platelets. This pooling
set has a polyurethane in-line leucocyte filter (Imugard III
S PL) in a soft housing but overall retained within a hard
case. The FRE leucocyte filter is just in a soft housing
which is designed to empty its content ‘automatically’ by
the elasticity of the housing material. The MAC leucocyte
filters are in a hard housing. Both FRE and MAC filters
have a polyester base, which differs from that of TER.
The latter supplier claims that the Imugard filter does not
retain leucocytes by adhesion, but only mechanically
through sieving. The polyester-based FRE leucocyte filter
has a net neutral charge as well, but probably combines
adhesive as well as mechanical retention of leucocytes
(personal communication from Fresenius Kabi). Taken
together, differences in physicochemical composition as
well as in housing may explain the observations. Of note,
different types of leucocyte filters have been compared
before in older studies, including the Imugard filter. Dif-
ferences in yield [9, 10] as well as in post hoc platelet
activation or quality [11] have been described.
The TER set consistently yielded more platelets than the
other two suppliers, but the PI process caused a significant
loss of that surplus platelet yield. Based on the data before
Fig. 5 Platelet metabolism. (a) Platelet
concentrate pH. The dashed line indicates the
lower acceptance criterion (Council of Europe
Guidelines). Median and interquartile range are
shown (b) The glucose concentration. The
dashed line indicates the lower limit of
detection of the blood gas analyser. Mean and
standard deviation are shown. (c) The lactic
acid concentration. Mean and standard
deviation are shown. (d) The lactic acid
production rate determined over 5 days of
storage and per 1011 platelets. Median and
interquartile range are shown. All data are
shown as individual symbols for day 1 (○) and
for day 6 (♢) of storage. Median and
interquartile range are given.
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and after PI, 156% of platelets were lost from the TER PC
in comparison with just 95% and 44% from the MAC
and FRE PC, respectively. This shows that it is important
to take into account PI when evaluating the overall yield
of different pooling sets, as the PI process may act differ-
ently on products produced by different pooling sets. It is
unclear what this might be in particular.
Small but significant differences in platelet metabolism
were found. It is not clear why TER PC had a significantly
lower pH on day 1 compared with both MAC and FRE. This
could not be explained by metabolism as such, because lac-
tic acid concentrations were not different on day 1. Platelets
produced by the TER pooling sets did have an increased lac-
tic acid production rate. This may follow the platelet con-
centration and/or content because we previously showed
that PI treatment can increase storage lesion when the plate-
let number is high [2, 12]. Whether this underlies the differ-
ence in lactic acid found in this study is not clear.
The PAC1 binding in response to TRAP was lowest for
MAC and highest for TER platelets on day 1, indicating
that TER platelets sense the agonist better at that time.
Over 5 days of storage however, all PC significantly lost
sensitivity for the intermediate TRAP concentrations
which is indicative of storage lesion. Only at high con-
centrations of TRAP, PAC1 binding was evident with the
least binding to TER platelets. This is in line with the
metabolic data showing that TER platelets had increased
lactic acid production rates. Of note, this increased meta-
bolic rate did not cause increased apoptosis as determined
by annexin V binding, nor increased alpha-degranulation
as determined by P-selectin expression. This indicates that
the differences between the three pooling sets in terms of
storage lesion effects are small.
All three suppliers fulfilled the criteria as set by the
Blood Institution. The choice for a particular pooling set
depends on many factors, including but not restricted to
platelet yield and platelet quality over storage time. The
combination with PI adds to the complexity of the pro-
duction process and the interpretation of validation data.
Therefore, although a high platelet yield can be preferred
Fig. 6 Binding of PAC1 in response to TRAP on
day 1 and day 6. The percentage of PAC1
positive platelets in response to increasing
concentrations of TRAP, 0 lM (black), 4 lM
(blue), 8 lM (red) and 40 lM (white) is shown.
Bars represent mean and whiskers standard
deviation for (a) day 1 and (b) day 6 of
storage. Statistics by two-way ANOVA is shown
on top of the panels, when not signiﬁcant
there is no indication; **P < 001 and
****P < 00001.
Fig. 7 Exposure of negatively charged phospholipids and P-selectin. (a) The percentage of platelets staining positive for annexin V. (b) The percentage
of platelets staining positive for P-selectin. All data are shown as individual symbols for day 1 (○) and for day 6 (♢) of storage. Mean is shown as a hor-
izontal line, and whiskers indicate standard deviation. Statistics by two-way ANOVA is shown on top of the panels, when not signiﬁcant there is no indi-
cation; *P < 005 and **P < 001.
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in many instances, the combination with PI can impose a
risk for premature dropout caused by storage lesion. The
data show that thorough comparison of platelet yield and
quality is important to direct decisions in a setting with
PI.
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